Type 1 fibroblast growth factor receptor antagonists - Pipeline Insight, 2024

This “Type 1 Fibroblast Growth Factor Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type 1 Fibroblast Growth Factor Receptor Antagonists Understanding

Type 1 Fibroblast Growth Factor Receptor Antagonists: Overview

Fibroblast growth factor receptors (FGFRs) play an important role in embryonic development, angiogenesis, wound healing, cell proliferation and differentiation. FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways. Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression.

Function - The FGFR1 protein spans the cell membrane, so that one end of the protein is inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with other proteins called fibroblast growth factors (FGFs) outside the cell and to receive signals that help the cell respond to its environment. When an FGF attaches to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. This signaling is thought to play an important role in the development and growth of several parts of the body, including the brain, bones of the head and face (craniofacial bones), bones in the hands and feet, and the long bones in the arms and legs.

Type 1 Fibroblast Growth Factor Receptor Antagonists- Frequent tumor fibroblast growth factor receptor (FGFR) alterations are seen in many cancers, and include genetic amplifications, mutations, rearrangements and fusions. FGFR inhibitors target these receptor alterations and show promise as a drug class. FGF signaling inhibition dramatically reduces revascularization, hitting upon one of the hallmarks of cancers, angiogenesis, and reduces tumor burden in human tumors that depend on autocrine FGF signaling

Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs Chapters

This segment of the Type 1 Fibroblast Growth Factor Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Type 1 Fibroblast Growth Factor Receptor Antagonists Emerging Drugs

ABSK 091: Abbisko Therapeutics ABSK 091 (formerly AZD 4547) is an orally bioavailable, small molecule, fibroblast growth factor receptor (FGFR) tyrosine kinase 1, 2 and 3 inhibitor, being developed and investigated by Abbisko therapeutics for the treatment of solid tumors. ABSK091 is an innovative small molecule FGFR inhibitor, of which Abbisko has the exclusive global rights for development, manufacture, and commercialization. In prior preclinical and multiple clinical studies, ABSK091 has demonstrated good safety and tolerability profiles, as well as preliminary efficacy in cancer patients harboring FGFR alterations.

Lucatinib: Clovis Oncology Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha andbeta.

Type 1 Fibroblast Growth Factor Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Type 1 Fibroblast Growth Factor Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Type 1 Fibroblast Growth Factor Receptor Antagonists

There are approx. 12+ key companies which are developing the Type 1 Fibroblast Growth Factor Receptor Antagonists. The companies which have their Type 1 Fibroblast Growth Factor Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Abbisko Therapeutics.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Type 1 Fibroblast Growth Factor Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 1 Fibroblast Growth Factor Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Fibroblast Growth Factor Receptor Antagonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Type 1 Fibroblast Growth Factor Receptor Antagonists R&D.

• The therapies under development are focused on novel approaches for Type 1 Fibroblast Growth Factor Receptor Antagonists.

Type 1 Fibroblast Growth Factor Receptor Antagonists Report Insights

• Type 1 Fibroblast Growth Factor Receptor Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type 1 Fibroblast Growth Factor Receptor Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Type 1 Fibroblast Growth Factor Receptor Antagonists drugs?
• How many Type 1 Fibroblast Growth Factor Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Type 1 Fibroblast Growth Factor Receptor Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Type 1 Fibroblast Growth Factor Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type 1 Fibroblast Growth Factor Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.